Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 1.02 is 18% below its 4-year average of 1.25, around the middle of its 4-year range (0.00–2.90).
As of the fiscal period ended Tuesday, March 31, 2026. 32.91% below its 12-month average of 1.52.
Reported quarterly debt to equity ratio; no daily interpolation.
DEBT TO EQUITY RATIO
1.02
DEBT TO EQUITY RATIO AVG TTM
1.52
DEBT TO EQUITY RATIO AVG 3Y
1.63
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-32.91%
CURRENT VS 3Y AVG
-37.33%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.67
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+52.59%
vs the sector median at left
Solventum Corporation
Market Cap
$14.02B
Debt to Equity Ratio
1.02
TTM Avg
1.52
3Y Avg
1.63
5Y Avg
N/A
Market Cap
$13.84B
Debt to Equity Ratio
0.34
TTM Avg
0.33
3Y Avg
0.35
5Y Avg
0.36
Market Cap
$12.13B
Debt to Equity Ratio
0.03
TTM Avg
0.03
3Y Avg
0.03
5Y Avg
0.03
Market Cap
$12.02B
Debt to Equity Ratio
1.63
TTM Avg
1.78
3Y Avg
2.05
5Y Avg
1.83
Market Cap
$16.57B
Debt to Equity Ratio
0.55
TTM Avg
0.36
3Y Avg
0.37
5Y Avg
0.29
Market Cap
$11.23B
Debt to Equity Ratio
0.23
TTM Avg
0.22
3Y Avg
0.21
5Y Avg
0.24
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Solventum Corporation (SOLV) | $14.02B | 1.02 | 1.52 | 1.63 | N/A |
| The Cooper Companies, Inc. (COO)vs › | $13.84B | 0.34 | 0.33 | 0.35 | 0.36 |
| DaVita Inc. (DVA)vs › | $15.15B | -23.12 | 55.08 | 35.65 | 25.99 |
| Align Technology, Inc. (ALGN)vs › | $12.13B | 0.03 | 0.03 | 0.03 | 0.03 |
| Revvity, Inc. (RVTY)vs › | $12.10B | 0.48 | 0.45 | 0.51 | 0.56 |
| Baxter International Inc. (BAX)vs › | $12.02B | 1.63 | 1.78 | 2.05 | 1.83 |
| Insulet Corp. (PODD)vs › | $11.56B | 0.69 | 0.93 | 1.71 | 1.82 |
| Medpace Holdings, Inc. (MEDP)vs › | $16.57B | 0.55 | 0.36 | 0.37 | 0.29 |
| Bio-Techne Corporation (TECH)vs › | $11.23B | 0.23 | 0.22 | 0.21 | 0.24 |
| Hologic, Inc. (HOLX)vs › | $16.97B | 0.52 | 0.52 | 0.55 | 0.69 |
Debt/Equity
1.02
Current Ratio
1.23
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-03-31 | 1.02 |
| 2025-12-31 | 1.00 |
| 2025-09-30 | 1.03 |
| 2025-06-30 | 2.14 |
| 2025-03-31 | 2.43 |
| 2024-12-31 | 2.71 |
| 2024-09-30 | 2.54 |
| 2024-06-30 | 2.90 |
| 2024-03-31 | 2.16 |
| 2023-12-31 | 0.71 |
| 2023-09-30 | 2.56 |
| 2023-06-30 | 0.01 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.00 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
